Aurobindo launches Adquey in US; Nuvama sees $300m peak sales
In short
Aurobindo Pharma launched Adquey in the US, and Nuvama sees peak sales of $300 million. The report says the drug was discovered by Otsuka and licensed to Aurobindo’s arm Acrotech for US use.
Adquey is for mild-to-moderate atopic dermatitis in adults and children aged two and above. The timing and pricing details are not stated in the available reporting.
What the reporting says
Aurobindo Pharma launched Adquey in the US, according to the market summary, with Nuvama estimating peak sales of $300 million. The snippet says the drug was originally discovered by Otsuka Pharmaceutical and licensed to Aurobindo’s arm Acrotech for US commercialization. It is used for mild-to-moderate atopic dermatitis in adults and children aged two years and above, but the source does not say when sales will peak or how Aurobindo priced the product.
Why it matters
Aurobindo Pharma launched Adquey in the US, and the cited market note says Nuvama sees peak sales of $300 million. The drug was originally discovered by Otsuka Pharmaceutical and licensed to Aurobindo’s arm Acrotech for US commercialization. The product is used for mild-to-moderate atopic dermatitis in adults and children aged two years and above. The source also says the US market for the category was around $1.3 billion for the 12 months ended July 2026.